[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643737":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":92,"collaborators":18,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":18,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":18,"enrollmentInfo":103,"targetDuration":18,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":18,"overallStatus":31,"whyStopped":18,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Rimegepant","EXPERIMENTAL","Participants will receive rimegepant 75 mg ODT to administer for the acute treatment of migraine attacks of moderate or severe headache pain intensity. A second rimegepant 75 mg ODT should be taken in the event that participants are not pain free at approximately 2 hours post initial dose OR upon headache relapse after initial pain freedom. The second dose should be taken within 24 hours of the initial dose. Participants will receive rimegepant over a 24 week period during the OLT phase.\n\nParticipants may redose with rimegepant up to a maximum of 10 times per month (28 days) during the OLT phase.",[13],"Drug: Rimegepant",[15],{"type":16,"name":9,"description":9,"armGroupLabels":17,"otherNames":18},"DRUG",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":18,"email":27},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[29,43,53,62,71,81],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":18},"Hope Clinical Research","RECRUITING","Canoga Park","California","91303","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-118.59814,34.20112,{"lat":41,"lon":40},{"facility":44,"status":31,"city":45,"state":46,"zip":47,"country":35,"countryCode":36,"cosmosGeoPoint":48,"geoPoint":52,"contacts":18},"Neurology Offices of South Florida","Boca Raton","Florida","33428",{"type":38,"coordinates":49},[50,51],-80.0831,26.35869,{"lat":51,"lon":50},{"facility":54,"status":31,"city":55,"state":46,"zip":56,"country":35,"countryCode":36,"cosmosGeoPoint":57,"geoPoint":61,"contacts":18},"Brainstorm Research","Miami","33176",{"type":38,"coordinates":58},[59,60],-80.19366,25.77427,{"lat":60,"lon":59},{"facility":63,"status":31,"city":64,"state":46,"zip":65,"country":35,"countryCode":36,"cosmosGeoPoint":66,"geoPoint":70,"contacts":18},"Clinical Neuroscience Solutions","Orlando","32801",{"type":38,"coordinates":67},[68,69],-81.37924,28.53834,{"lat":69,"lon":68},{"facility":72,"status":31,"city":73,"state":74,"zip":75,"country":35,"countryCode":36,"cosmosGeoPoint":76,"geoPoint":80,"contacts":18},"New England Regional Headache Center","Worcester","Massachusetts","01609",{"type":38,"coordinates":77},[78,79],-71.80229,42.26259,{"lat":79,"lon":78},{"facility":82,"status":83,"city":84,"state":85,"zip":86,"country":35,"countryCode":36,"cosmosGeoPoint":87,"geoPoint":91,"contacts":18},"Michigan Headache & Neurological Institute","NOT_YET_RECRUITING","Ann Arbor","Michigan","48104",{"type":38,"coordinates":88},[89,90],-83.74088,42.27756,{"lat":90,"lon":89},{"type":93,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100643737","phase-4-a-study-to-learn-about-the-safety-of-taking-an-additional-dose-of-the-medicine-rimegepant-in-adults-with-migraine-100643737",false,"NCT07609914","A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine","A PHASE 4, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF REDOSING OF RIMEGEPANT IN PARTICIPANTS 18 YEARS OF AGE OR OLDER FOR THE ACUTE TREATMENT OF MIGRAINE","Inclusion:\n\n* Eligible participants include adult participants aged 18 years of age or older with a minimum 1-year history of migraine (with or without aura) consistent with International Classification of Headache Disorders, 3rd Edition\n* Eligible participants must be currently using acute migraine treatment in accordance with the local label and have all of the following on average across the 12 weeks prior to the Screening Visit and, during the first 28 days of the observation phase (OP): (1) 6-14 monthly migraine days (MMDs); (2) \\\u003C15 monthly headache days (MHDs) (migraine or non-migraine); and (3) \\\u003C7 monthly non-migraine headache days.\n\nExclusion:\n\n* Participants with headaches occurring ≥15 days per month (migraine or non-migraine) on average across the 12 weeks prior to the Screening Visit and ≥7 non-migraine headache days per month on average across the 12 weeks prior to the Screening Visit would not be eligible.","ALL","18 Years",{"count":104,"type":105},400,"ESTIMATED","INTERVENTIONAL",[108],"PHASE4","Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack.\n\nThe primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.",[111],"Acute Treatment of Migraine","2026-06-29",{"date":114,"type":115},"2026-07-01","ACTUAL",{"date":117,"type":115},"2026-05-28",{"date":119,"type":105},"2028-05-15",{"name":5,"class":6},6]